In vivo CAR-T: toward scalable and programmable immunotherapy
Cell and Gene Therapy Insights · 26.05.2026 · 12 (4) · 449-452
DOI: 10.18609/cgti.2026.048 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cell and Gene Therapy Insights, online erschienen am 26.05.2026. Verfasst von Kartika Venugopal. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
This article is part of our ‘Rising Stars’ series, giving a platform to the emerging leaders of the sector. In this series, we share the perspectives of fledgling thought-leaders, chosen by our Editorial Advisory Board members as future stars in their field. Kartika is an experienced immunologist and CAR-T scientist who brings a strong foundation in rigorous scientific training into the biotechnology industry. She has rapidly grown into an independent, fast-learning, and impactful scientific driver. During her time at Tessera Therapeutics, she contributed to the development of the company’s proprietary all-RNA Gene Writer platform for in vivo CAR-T, where she played a key role in advancing technical optimization and driving project progression. Her ability to integrate multidisciplinary advances into a coherent vision underscores her growing impact as an innovation leader.
Zitieren
APA
Venugopal, K. (2026). In vivo CAR-T: toward scalable and programmable immunotherapy. Cell and Gene Therapy Insights, 12(4), 449-452. https://doi.org/10.18609/cgti.2026.048
Vancouver
Venugopal K. In vivo CAR-T: toward scalable and programmable immunotherapy. Cell and Gene Therapy Insights. 2026;12(4):449-452. doi:10.18609/cgti.2026.048
BibTeX
@article{Venugopal2026,
author = {Venugopal, Kartika},
title = {In vivo CAR-T: toward scalable and programmable immunotherapy},
journal = {Cell and Gene Therapy Insights},
year = {2026},
volume = {12},
number = {4},
pages = {449--452},
doi = {10.18609/cgti.2026.048}
}
EUVIMED